FDA Brief

Warning letters Devices

FDA warning letter to

Meridian Bioscience, Inc

High riskIssued Dec 22, 2025Posted Jan 27Center for Devices and Radiological Health

FDA warns Meridian Bioscience's Magellan Diagnostics over quality system failures and unreported problems with its blood lead test kits.

What happened

FDA inspected Magellan Diagnostics, Inc. in North Billerica, MA from August 5 to August 26, 2025, and found the firm's quality system for its blood lead testing devices did not meet the Quality System regulation. FDA also found the firm did not open corrective actions for about 179 false positive complaints and missed the required 30-day report for a false negative result tied to a corroded sensor pin. The firm's written responses were largely judged not adequate.

What FDA found

  1. The firm did not follow its own corrective and preventive action procedure, failing to open actions when false positive and out-of-range control complaints rose.

    21 CFR 820.100(a)
  2. The firm never set written design requirements for the Level 1 and Level 2 controls used with the LeadCare II system.

    21 CFR 820.30(c)
  3. The firm did not validate the cleaning and decontamination steps in its instructions for use, and did not update its risk files after new hazards such as false positives and mislabeled product appeared.

    21 CFR 820.30(g)
  4. The firm changed critical manufacturing acceptance criteria without validating the revised process, and its calibration verification procedure lets operators leave out high results and outliers.

    21 CFR 820.75(a)
  5. Incoming inspection of the capillary collection tubes checked only packaging and no critical quality attributes.

    21 CFR 820.80(b)
  6. The firm did not report a device malfunction to FDA within 30 days, including a false negative pediatric result caused by a corroded sensor pin.

    21 CFR 803.50(a)(2)

What FDA wants

FDA asks the firm to write back within 15 business days with the steps taken, documentation of fixes that address root causes, and a timetable for anything still open. FDA also requires certification from an outside expert who audits the firm's manufacturing and quality systems, due July 31, 2026, with follow-up certifications in 2027 and 2028.

Who should pay attention

  • labs and clinics that run blood lead tests on these analyzers
  • distributors and brands that sell LeadCare products
  • diagnostics makers that handle complaints and device malfunction reporting

This is a summary. Read the original letter on fda.gov.

Meridian Bioscience, Inc's FDA history

Recalls in the last 12 months

Jan 14 Class II Meridian Bioscience Inc
Device
Revogene C. difficile, in vitro diagnostic assay intended for use with the Revogene instrument, Catalog Number 410300
The affected lots show a decline in performance over time, which may lead to false-negative results.
Nov 26, 2025 Class II Meridian Bioscience Inc
Device
Meridian Bioscience, alethia c. Difficile, Catalog Number 480050, Nucleic Acid Amplification Test Assay
The cap on the reaction buffer tube may be missing the black rubber gasket resulting in the potential for leakage and reduced buffer volume.
Nov 26, 2025 Class II Meridian Bioscience Inc
Device
Meridian Bioscience, Group B Streptococcus, Catalog Number 480050, Nucleic Acid Amplification Test Assay
The cap on the reaction buffer tube may be missing the black rubber gasket resulting in the potential for leakage and reduced buffer volume.

Full company page

Similar letters to other companies

  1. LGM Pharma Solutions, LLC

    FDA warned LGM Pharma Solutions over manufacturing-quality failures in failing-result investigations and process validation for tablets, including a recalled product.

    High risk
  2. USV Private Limited

    FDA warned USV Private Limited that its sterile injectable manufacturing in Daman, India, had aseptic-processing, facility-design and visible-particulate violations.

    High risk
  3. Next Medical Products Company, LLC

    FDA warns Next Medical Products that its ultrasound gels were contaminated and made without required quality controls or clearance.

    High risk
  4. Conroe Welding Supply, Inc.

    FDA warns Conroe Welding Supply over medical oxygen manufacturing failures, including untested batches and a container with 99% (b)(4).

    High risk